IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses

Immune checkpoint inhibitor (ICI) therapy has revolutionized anti-cancer treatment for many late-stage cancer patients. However, ICI therapy has thus far demonstrated limited efficacy for most patients, and it remains unclear why this is so. Interleukin 10 (IL-10) is a cytokine that has been recogni...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of molecular sciences Vol. 22; no. 21; p. 11848
Main Authors:	Harper, Taylor A., Bacot, Silvia M., Fennell, Christie Jane, Matthews, Rebecca L., Zhu, Christina, Yue, Peng, Benton, Alexander, Friedman, Devira, Akue, Adovi, KuKuruga, Mark A., Lee, Shiowjen, Wang, Tao, Feldman, Gerald M.
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 31.10.2021 MDPI
Subjects:	Apoptosis Cancer Clinical trials Cytokines FDA approval Humans Immunotherapy Interferon-gamma - immunology Interleukin-10 - immunology Interleukin-2 Receptor alpha Subunit - immunology Ki-67 Antigen - immunology Lymphocyte Activation - drug effects Lymphocytes MAP Kinase Signaling System - drug effects MAP Kinase Signaling System - immunology Melanoma Nivolumab - pharmacology T-Lymphocytes - immunology Targeted cancer therapy STAT3 pathway nivolumab AKT serine–threonine kinase pathway MAP kinase pathway cytokines T cells interleukin 10
ISSN:	1422-0067, 1661-6596, 1422-0067
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!